Business
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management planned for initiation in the second half of 2026Petrelintide demonstrated double-digit weight loss with placebo-like tolerability in the ZUPREME-1 Phase 2 trialZealand Pharma and Roche aim to unlock the full value potential of petrelintide providing a highly tolerable option for people living with ov
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hruCjDK29WWlg5.YGk148A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OQ--/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 11 / 2026","length":36,"tagName":"p"},{"type":"text","content":"Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management","length":115,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 trials for chronic weight management planned for initiation in the second half of 2026","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Petrelintide demonstrated double-digit weight loss with placebo-like tolerability in the ZUPREME-1 Phase 2 trial","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Zealand Pharma and Roche aim to unlock the full value potential of petrelintide providing a highly tolerable option for people living with overweight and obesity","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":367,"olType":false},{"type":"text","content":"Copenhagen, Denmark, April 29, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche. The initiation is planned for the second half of 2026.","length":367,"tagName":"p"},{"type":"text","content":" Adam Steensberg, President and Chief Executive Officer of Zealand Pharma, said,“Advancing petrelintide into Phase 3 marks an important step for the program and our collaboration with Roche. By delivering exceptional tolerability and desired weight loss without disrupting daily life, we aim to redefine the weight management experience for people living with overweight and obesity." ","length":394,"tagName":"p"},{"type":"text","content":"The Phase 3 program for petrelintide is designed to evaluate the...